Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
OTC Switching of Emergency Contraceptive Levonorgestrel Will Be Difficult Under Current System: JPA
The Japan Pharmaceutical Association (JPA) has submitted public comments on the switching of the emergency contraceptive levonorgestrel to OTC status to the health ministry, saying that “switching of the drug will be difficult under the current system,” it reported on…
To read the full story
Related Article
- Japan’s 1st OTC Morning-After Pill Now Available
February 3, 2026
- Daiichi Sankyo Unveils Brand Site for OTC NorLevo Ahead of Launch
January 15, 2026
- Daiichi Sets February Launch for Japan’s 1st OTC Morning-After Pill
December 19, 2025
- Japan Approves Nonprescription Version of Morning-After Pill: ASKA
October 21, 2025
- Japan Panel Green Lights Nonprescription Switch of Morning-After Pill
September 1, 2025
- Japan Moves Toward OTC Morning-After Pill Sales Without Age Limit or Parental Consent
August 29, 2025
- Set Deadline for Non-Prescription Pilot of Morning-After Pill: Panel Members
February 13, 2025
- Purchasers Satisfied, Pharmacy Service “Appropriate” in Non-Prescription Pilot for Emergency Contraceptives
May 14, 2024
- MHLW to Run Pilot Sale of Emergency Contraceptives without Prescription
June 29, 2023
- Citizens’ Group Opposes Pilot Switch Program for Emergency Contraceptives
June 27, 2023
- Will Pilot Switch Proposal Break Stalemate in Emergency Contraceptive Debate?
June 23, 2023
- MHLW Mulls New OTC Class to Bar Online Sales amid Unease over Morning After Pills
June 14, 2023
- LDP Lawmakers Oppose Online Sale of Morning After Pills 3 Years after Switch
June 8, 2023
- MHLW Taking Public Comments on OTC Access to Emergency Contraceptives
January 6, 2023
ORGANIZATION
- Regional Formularies Seen Driving Shift to Quality, Industry Consolidation: Society Head
April 27, 2026
- JPMA Mulls Proposal to Standardize PMDA Review Reports
April 27, 2026
- JPWA Urges Caution on Fixed Margins, Citing French Model Shortcomings
April 24, 2026
- APAC Disbands Drug Discovery WG as Asia Capabilities Rise
April 23, 2026
- Flight Cuts, Fuel Costs Tied to Iran Crisis Threaten API Imports: Trader
April 23, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…